"SoloSTARis the result of over four years of intensive research and development. This pen has been designed based on inputs from diabetic patients, their nurses and doctors. Thus we are confident that this will cater to the needs of the patients", he added.
It is an easy-to-use insulin pen brings greater flexibility to patients and an opportunity for earlier initiation of insulin therapy which may contribute to better glycaemic control. This pen is designed in a very convenient manner to enable patients carry it easily, especially while travelling", added he said. Currently, the market for insulin stood at Rs 460 crore and it is growing at a rate of 80 per cent.
"We will like to improve our market share to nine per cent from seven per cent at present," he added.
